Ellipta Programme
G&T has been involved with the delivery of the Ellipta programme for GSK for over nine years which has entailed the development and launch of a next generation inhaler system.
Our involvement began with the early stage commercial launch of the product and continues through to the eventual development of global mass production and manufacturing facilities capable of producing up to 120 million devices per year.
For Phase 1 of the project, we provided a full suite of Project and Programme Controls for the investment of over £500m of capital expenditure which ensured Ellipta's launch dates were met on time in multiple global markets. We provided continuous support at programme level including accurate early stage information to support decision-making and enhance confidence in fast paced investment decisions.
The programme included delivery of both new build and refurbished manufacturing and laboratory space, new assembly and packing lines, blending suites and dry powder filling lines, laboratory equipment, new third party plastics sub-assembly and moulding capability, together with warehouse space.
Key Contacts
Client
GlaxoSmithKline (GSK)
Location
UK, USA and Europe
